Validated tool predicts survival of men taking abiraterone after docetaxel

《Validated tool predicts survival of men taking abiraterone after docetaxel》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、RESEARCHHIGHLIGHTSNatureReviewsUrologyadvanceonlinepublication15April2014;doi:10.1038/nrurol.2014.85PROSTATECANCERValidatedtoolpredictssurvivalofmentakingabirateroneafterdocetaxelEnormousprogresshasbeenmadeinPatientstratification—basedonsixthetreatmentofcastration-resistantbaselineclinic

2、alparameters(ECOGprostatecancer(CRPC)overtheperformancestatusof2;presencepastdecadeand,asaresult,updatedof livermetastases;timefromstart ofprognosticmodelsareneededthathormonetherapytoabirateronereflecttheextendedsurvivalassociatedtreatmentof≤36months;lowalbumin;withnewtherapies.Investig

3、atorsatthehighalkalinephosphatase;highlactateInstituteofCancerResearchintheUK,dehydrogenase)—waspredictiveofoverallledbyJohann de Bono,haveexternallysurvivalinthiscohort,withanAUCofvalidatedaprognosticmodelformen0.71.Researchersalsotestedthetoolintreatedwithsecond-lineabiraterone.menwhor

4、eceivedabirateronebeforeThemodelwascreatedusingdatachemotherapy(n=65),butfounditwasfromtheCOU-AA-301phaseIIItrial,forlessaccurateinthispopulation(AUCwhichmenwithmetastaticCRPCwho0.61).Prospectiveevaluationandclinicalhadfaileddocetaxel-basedchemotherapyimplementationarehopedtofollow.werer

5、andomizedtoreceiveeitherSarahPaytonabirateroneorplacebo.Now,deBonoandcolleagueshavevalidatedtheprognostictoolinanindependentcohortOriginalarticleRavi,P.etal.Externalvalidationofaof94menwhoreceivedabirateroneafterprognosticmodelpredictingoverallsurvivalinmetastaticdocetaxelattheirinstitut

6、ionbetweencastrate-resistantprostatecancerpatientstreatedwithabiraterone.Eur.Urol.doi:10.1016/j.eururo.2014.03.0202006and2013,outsideofaclinicaltrial.NATUREREVIEWS

7、UROLOGYADVANCEONLINEPUBLICATION©2014MacmillanPublishersLimited.AllrightsreservedEURURO-5595;No.ofPages4EUROPEANUROLOGYXXX(20

8、14)XXX–XXXavailableatwww.sciencedirect.comjournalhomepage:www.europeanurology.comBriefCorrespondenceExternalValidationofaPrognosticModelPredictingOverallSurvivalinMetastaticCastrate-resistantProstateCancerPatientsTreatedwithAbirateronePrafulRavi,JoaquinMateo,DavidLorente,